United States · 
What does Merlin Biomed invest in?
Merlin Biomed invests most often at Series D and Venture (73% of the rounds on record), in sectors such as Operating Systems and Software.
Merlin Biomed highlights
- 01
11 rounds on record
- 02
Mostly Series D and Venture: 73% of its rounds
- 03
6 exits from the portfolio
What they do
- Type
- Growth equity (from a list, unverified)
- Cheque size
- Not stated
- Sectors
- Operating SystemsSoftware
- Based in
- United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first11 appearances
- 2009
1 round
- Nov
- 2008
1 round
- Jul
- 2007
2 rounds
- Apr
- Jan
- 2006
3 rounds
- Nov
- Sept
- Jun
- 2005
1 round
- Feb
- 2004
1 round
- Jun
- 2003
2 rounds
- Oct
- Feb
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
Exits from the portfolio
Companies it backed that were later bought or listed6 in all
EUSA PharmaBought by Jazz Pharmaceuticals$650MApr 2012
Calypso MedicalBought by Varian Medical SystemsUndisclosedSept 2011
Salient Surgical TechnologiesBought by Medtronic$525MJul 2011
Gemin X PharmaceuticalsBought by Cephalon$525MMar 2011
Genelabs TechnologiesBought by GlaxoSmithKline$57MNov 2008
EUSA PharmaBought by EUSA Pharma$23MMar 2008
An exit counts when it came after the firm's first round in the company. From historical deal records.